The Stoch RSI shows that we still may have some power for a move up, but volume has been on the decline, even if it is still well above average. In addition, we're looking pretty extended on the daily chart. I closed half my position in anticipation of a potential retrace, before a new leg up. I have studied ZYNE's historical movements, and its behaviour is quite...
ZYNE BUY TP_25.88_199.19%_17.33pips_SL_7.36_14.91%_1.29pips
Bulls and bears are fighting hard to gain control. Levels on watch, if the range breaks bearish, we'll see deeper consolidation. Breaking bullish may see us look for a daily lower high.
Were we looking at residual buying pressure yesterday, or is ZYNE ready for another leg up? Analyst targets are all well above $10, and the projected upside is about 300%, but to assume that it will just skyrocket in that direction seem unreasonable. Bears took control in the second half of yesterday's session. The level to hold is $8.38. the levels to break are...
At $8.17, ZYNE was up 47% this week. Volume saw more than 50% of its share count exchange hands - though we probably saw a few million shares traded several times - and yesterday we saw a healthy bounce. There is still some volume, we could be looking at residue buying power and we need to have the levels on watch to find short term direction. Today we need to...
When a stocks surges 4% on opening. That's my signal to break out the trading surfboard and ride the wave. Plan, profit, and use a bit more to risk more gains. For me the goal was 30% and risking 10% of profit to get there.
Zynerba is one of my favourite biopharma stocks. I've played her from $3.88 up to $5.22, then sold when I saw that the hype was temporarily over. I didn't want to go long ZYNE, because biopharma is some scary stuff. When they presented failed trials earlier, the stock plunged 53%. On the other hand, when a trial succeeds, and a medicine can be filed and prepped...
Quarterly Semi-Annual Annual (Values in 000s | USD) Period Ending Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Total Revenue 990 952 617 339 Cost of Revenue 163 133 146 106 Gross Profit 826 819 470 233 Operating Expenses Research and Development 63 0 0 0 Sales, General and Admin. 435 478 679 413 Non-Recurring Items - - - - Other...
Watching for break in range seekingalpha.com